Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: Combination of polymers showing drug-polymer interaction for synergistic effects

Journal of Pharmaceutical Sciences

Volumn 103, Issue 11, 2014, Pages 3511-3523

  Prasad, Dev ^a   Chauhan, Harsh ^b   Atef, Eman ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

Amorphous; Crystallization inhibition; Indomethacin; Interaction; Polymer; Poorly water soluble drugs; Solid dispersion; Solubility; Supersaturation

Indexed keywords

EUDRAGIT; INDOMETACIN; POVIDONE; ACRYLIC ACID DERIVATIVE; DRUG CARRIER; POLYMER;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DENSITY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; ENTROPY; EVAPORATION; GLASS TRANSITION TEMPERATURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MELTING POINT; MISCIBILITY; MOLECULAR INTERACTION; MOLECULAR WEIGHT; PRECIPITATION; RAMAN SPECTROMETRY; SOLID STATE; SOLUBILIZATION; THERMAL ANALYSIS; X RAY POWDER DIFFRACTION; CHEMICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; INFRARED SPECTROPHOTOMETRY; KINETICS; MEDICINAL CHEMISTRY; PHARMACEUTICS; PROCEDURES; SOLUBILITY; TRANSITION TEMPERATURE;

ACRYLATES; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG STABILITY; INDOMETHACIN; KINETICS; MODELS, CHEMICAL; POLYMERS; POVIDONE; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; SPECTRUM ANALYSIS, RAMAN; TECHNOLOGY, PHARMACEUTICAL; TRANSITION TEMPERATURE;

EID: 84915784003     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24137     Document Type: Article

References (42)

1. Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12(23-24):1068-1075.
2. Law D, Schmitt EA, Marsh KC, Everitt EA, Wang W, Fort JJ, Krill SL, Qiu Y. 2004. Ritonavir-PEG 8000 amorphous solid dispersions: In vitro and in vivo evaluations. J Pharm Sci 93(3):563-570.
3. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. 2011. Formulation design for poorlywater-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int J Pharm 420(1):1-10.
4. Guzman HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, Chen H, Moreau JP, Almarsson O, Remenar JF. 2007. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 96(10):2686-2702.
5. Grana A, Limpach A, Chauhan H. 2013. Formulation considerations and applications of solid lipid nanoparticles. Am Pharm Rev 16(1).
6. Chiou WL, Riegelman S. 1971. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 60(9):1281-1302.
7. Kaushal AM, Gupta P, Bansal AK. 2004. Amorphous drug delivery systems: Molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst 21(3):133-193.
8. Zhou D, Zhang GG, Law D, Grant DJ, Schmitt EA. 2002. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci 91(8):1863-1872.
9. Graeser KA, Patterson JE, Zeitler JA, Gordon KC, Rades T. 2009. Correlating thermodynamic and kinetic parameters with amorphous stability. Euro J Pharm Sci 37(3-4):492-498.
10. Van den Mooter G, Weuts I, De Ridder T, Blaton N. 2006. Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int J Pharm 316(1-2):1-6.
11. Chauhan B, Shimpi S, Paradkar A. 2005. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Euro J Pharm Sci 26(2):219-230.
12. Vasanthavada M, Tong WQ, Joshi Y, Kislalioglu MS. 2004. Phase behavior of amorphous molecular dispersions I: Determination of the degree and mechanism of solid solubility. Pharm Res 21(9):1598-1606.
13. Taylor LS, Zografi G. 1997. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14(12):1691-1698.
14. Yoshioka M, Hancock BC, Zografi G. 1994. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 83(12):1700-1705.
15. Kai T, Akiyama Y, Nomura S, Sato M. 1996. Oral absorption improvement of poorly soluble drug using solid dispersion technique. Chem Pharm Bull 44(3):568-571.
16. Serajuddin AT. 1999. Solid dispersion of poorlywater-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88(10):1058-1066.
17. Hirasawa N, Ishise S, Miyata H, Danjo K. 2003. An attempt to stabilize nilvadipine solid dispersion by the use of ternary systems. Drug Dev Ind Pharm 29(9):997-1004.
18. Gupta P, Bansal AK. 2005. Spray drying for generation of a ternary amorphous system of celecoxib, PVP, and meglumine. Pharm Dev Technol 10(2):273-281.
19. Janssens S, Denivelle S, Rombaut P, Van den Mooter G. 2008. Influence of polyethylene glycol chain length on compatibility and release characteristics of ternary solid dispersions of itraconazole in polyethylene glycol/hydroxypropylmethylcellulose 2910 E5 blends. Euro J Pharm Sci 35(3):203-210.
20. Al-Obaidi H, Buckton G. 2009. Evaluation of griseofulvin binary and ternary solid dispersions with HPMCAS. AAPS PharmSciTech 10(4):1172-1177.
21. Noolkar SB, Jadhav NR, Bhende SA, Killedar SG. 2013. Solid-state characterization and dissolution properties of meloxicam-moringa coagulant-PVP ternary solid dispersions. AAPS Pharm-SciTech 14(2):569-577.
22. Al-Obaidi H, Ke P, Brocchini S, Buckton G. 2011. Characterization and stability of ternary solid dispersions with PVP and PHPMA. Int J Pharm 419(1-2):20-27.
23. Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P, Kinget R. 2001. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Euro J Pharm Sci 12(3):261-269.
24. Tobyn M, Brown J, Dennis AB, Fakes M, Gao Q, Gamble J, Khimyak YZ, McGeorge G, Patel C, Sinclair W. 2009. Amorphous drug-PVP dispersions: Application of theoretical, thermal and spectroscopic analytical techniques to the study of a molecule with intermolecular bonds in both the crystalline and pure amorphous state. J Pharm Sci 98(9):3456-3468.
25. Chauhan H, Hui-Gu C, Atef E. 2013. Correlating the behavior of polymers in solution as precipitation inhibitor to its amorphous stabilization ability in solid dispersions. J Pharm Sci 102(6):1924-1935.
26. Liu H, Zhang X, Suwardie H, Wang P, Gogos CG. 2012. Miscibility studies of indomethacin and Eudragit® E PO by thermal, rheological, and spectroscopic analysis. J Pharm Sci 101(6):2204-2212.
27. Chauhan H, Kuldipkumar A, Barder T, Medek A, Gu CH, Atef E. 2014. Correlation of inhibitory effects of polymers on indomethacin precipitation in solution and amorphous solid crystallization based on molecular interaction. Pharm Res 31(2):500-515.
28. Crowley KJ, Zografi G. 2003. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state. Pharm Res 20(9):1417-1422.
29. Quinteros DA, Rigo VR, Kairuz AFJ, Olivera ME, Manzo RH, Allemandi DA. 2008. Interaction between a cationic polymethacrylate (Eudragit E100) and anionic drugs. Euro J Pharm Sci 33(1):72-79.
30. Prasad D, Chauhan H, Atef E. 2013. Studying the effect of lipid chain length on the precipitation of a poorly water soluble drug from self-emulsifying drug delivery system on dispersion into aqueous medium. J Pharm Pharmacol 65(8):1134-1144.
31. Caron V, Tajber L, Corrigan OI, Healy AM. 2011. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. Mol Pharm 8(2):532-542.
32. Lin D, Huang Y. 2010. A thermal analysis method to predict the complete phase diagram of drug-polymer solid dispersions. Int J Pharm 399(1):109-115.
33. Huang J, Li Y, Wigent RJ, Malick WA, Sandhu HK, Singhal D, Shah NH. 2011. Interplay of formulation and process methodology on the extent of nifedipine molecular dispersion in polymers. Int J Pharm 420(1):59-67.
34. Aceves-Hernandez JM, Nicolás-Vázquez I, Aceves FJ, Hinojosa-Torres J, Paz M, Castañ O VM. 2009. Indomethacin polymorphs: Experimental and conformational analysis. J Pharm Sci 98(7):2448-2463.
35. Janssens S, Van den Mooter G. 2009. Review: Physical chemistry of solid dispersions. J Pharm Pharmacol 61(12):1571-1586.
36. Atef E, Chauhan H, Prasad D, Kumari D, Pidgeon C. 2012. Quantifying solid-state mixtures of crystalline indomethacin by Raman spectroscopy comparison with thermal analysis. ISRN Chromatography. 1:1-6.
37. Singh MC, Sayyad A, Sawant S. 2010. Review on various techniques of solubility enhancement of poorly soluble drugs with special emphasis on solid dispersion. J Pharm Res 3(10).
38. Habib MJ. 2001. Pharmaceutical solid dispersion technology. CRC Press Taylor & Francis, Boca Raton, Fl.
39. Sathigari SK, Radhakrishnan VK, Davis VA, Parsons DL, Babu RJ. 2012. Amorphous-state characterization of efavirenz-polymer hotmelt extrusion systems for dissolution enhancement. J Pharm Sci 101(9):3456-3464.
40. Marsac PJ, Shamblin SL, Taylor LS. 2006. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 23(10):2417-2426.
41. Aso Y, Yoshioka S, Kojima S. 2004. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly (vinylpyrrolidone) solid dispersions. J Pharm Sci 93(2):384-391.
42. Brostow W, Chiu R, Kalogeras IM, Vassilikou-Dova A. 2008. Prediction of glass transition temperatures: Binary blends and copolymers. Mater Lett 62(17):3152-3155.